Hikma PharmaceuticalsHKMPF +4.28%82 EV-to-FCF is 49.04 as of Jun. 30, 2026, which is 137% above its 10-year median of 20.71. GuruFocus rates HKMPF with a GF Score™ of 82/100 and a GF Value™ of $26.53 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 558 Drug Manufacturers companies, Hikma Pharmaceuticals ranks worse than 74.01% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Hikma Pharmaceuticals's Enterprise Value is $5,836 Mil.
Hikma Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $119 Mil. Therefore, Hikma Pharmaceuticals's EV-to-FCF for today is 49.04.
The historical rank and industry rank for Hikma Pharmaceuticals's EV-to-FCF or its related term are showing as below:
HKMPF'
s EV-to-FCF Range Over the Past 10 Years
Min: 10.07 Med: 20.71 Max: 68.29
Current: 49.04
During the past 13 years, the highest EV-to-FCF of Hikma Pharmaceuticals was 68.29. The lowest was 10.07. And the median was 20.71.
HKMPF's EV-to-FCF is ranked worse than 74.01% of 558
companies
in the Drug Manufacturers industry
Industry Median: 20.045
vs HKMPF: 49.04
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Hikma Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Hikma Pharmaceuticals's share price for today is $20.115.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hikma Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $1.810.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hikma Pharmaceuticals EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Hikma Pharmaceuticals's EV-to-FCF falls into.
Hikma Pharmaceuticals's current Enterprise Value is $5,836 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hikma Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $119 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hikma Pharmaceuticals (HKMPF) has a EV-to-FCF of 49.04 as of Jun. 30, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Hikma Pharmaceuticals and its competitors. This is 137% above median its historical median of 20.71. Over the past decade, Hikma Pharmaceuticals' EV-to-FCF has ranged from 10.07 to 68.29. According to the industry distribution chart, Hikma Pharmaceuticals ranks #413 out of 558 companies in the Drug Manufacturers industry, placing it in the top 74%.
Is Hikma Pharmaceuticals' EV-to-FCF too high?
Hikma Pharmaceuticals' current EV-to-FCF of 49.04 is 137% above median its 10-year median of 20.71. Over the past 10 years, this metric has ranged from a low of 10.07 to a high of 68.29. The Drug Manufacturers industry median EV-to-FCF is 20.05. Hikma Pharmaceuticals' value of 49.04 is 144.6% above this industry median. Based on the distribution chart, Hikma Pharmaceuticals ranks #413 out of 558 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Hikma Pharmaceuticals has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hikma Pharmaceuticals ranks #413 out of 558 companies for EV-to-FCF. This places Hikma Pharmaceuticals in the lower half of its industry. The industry median EV-to-FCF is 20.05. Hikma Pharmaceuticals' value of 49.04 is 144.6% above this benchmark. Historically, Hikma Pharmaceuticals' own EV-to-FCF has ranged from 10.07 to 68.29 over the past decade. While the company's 10-year median is 20.71 vs. the industry median of 20.05, Hikma Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.05, based on 558 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hikma Pharmaceuticals's current EV-to-FCF of 49.04 is 144.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Hikma Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hikma Pharmaceuticals's current EV-to-FCF is 49.04, which is 137% above median its own 10-year median of 20.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (HKMPF) is currently considered Modestly Undervalued. The stock's GF Value™ is $26.53, compared to a current price of $20.12 — trading 24.2% below its estimated fair value. The current EV-to-FCF is 49.04, which is 137% above median its 10-year median of 20.71 and 144.6% above the Drug Manufacturers industry median of 20.05. Hikma Pharmaceuticals' overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Hikma Pharmaceuticals (HKMPF), the current EV-to-FCF is 49.04 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hikma Pharmaceuticals (HKMPF) Overvalued in 2026?
Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued.
The current stock price of $20.12 is trading 24.2% below its estimated GF Value™ of $26.53.
GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for HKMPF:
EV-to-FCF: 49.04 (137% above median its 10-year median of 20.71)
GF Value™: $26.53 vs. price of $20.12 (24.2% below fair value)
Industry Position: 144.6% above the Drug Manufacturers median (#413 of 558)
No single metric tells the full story. See the HKMPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
82GF Score
Get the complete analysis for HKMPF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKMPF has been successfully added to your 
